{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:15:56Z","timestamp":1761164156625,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cld.2019.04.011","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T08:58:25Z","timestamp":1559811505000},"page":"511-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Screening and Prophylaxis to Prevent Hepatitis B Reactivation"],"prefix":"10.1016","volume":"23","author":[{"given":"Joe","family":"Sasadeusz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng Lee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"McColl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue Anne","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Shackel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Rickard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"De Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2019.04.011_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2019.04.011_bib2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.04.011_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A\u00a0revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2019.04.011_bib4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2019.04.011_bib5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2019.04.011_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2019.04.011_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cld.2019.04.011_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.dld.2016.08.113","article-title":"High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy","volume":"48","author":"Castelli","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2019.04.011_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3109\/10428194.2013.813502","article-title":"Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance","volume":"55","author":"Chew","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.cld.2019.04.011_bib10","first-page":"180","article-title":"Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy","volume":"65","author":"Ceccarelli","year":"2012","journal-title":"J\u00a0Infect"},{"issue":"20","key":"10.1016\/j.cld.2019.04.011_bib11","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","article-title":"Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma","volume":"116","author":"Matsue","year":"2010","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.cld.2019.04.011_bib12","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cld.2019.04.011_bib13","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.3748\/wjg.v20.i24.7675","article-title":"Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy","volume":"20","author":"Jang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2019.04.011_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10549-011-1455-9","article-title":"A\u00a0single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?","volume":"127","author":"Long","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.cld.2019.04.011_bib15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cld.2019.04.011_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"10.1016\/j.cld.2019.04.011_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cld.2019.04.011_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B\u00a0cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"issue":"33","key":"10.1016\/j.cld.2019.04.011_bib19","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2019.04.011_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cld.2019.04.011_bib21","first-page":"7","article-title":"Individualized management of follicular lymphoma","volume":"4","author":"Bai","year":"2015","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"10.1016\/j.cld.2019.04.011_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2040620715622613","article-title":"Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas","volume":"7","author":"Gabellier","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1016\/j.cld.2019.04.011_bib23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","article-title":"Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?","volume":"21","author":"Reddy","year":"2016","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.cld.2019.04.011_bib24","first-page":"424","article-title":"Occult HBV reactivation induced by ibrutinib treatment: a case report","volume":"78","author":"de Jesus Ngoma","year":"2015","journal-title":"Acta Gastroenterol Belg"},{"issue":"1","key":"10.1016\/j.cld.2019.04.011_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis","volume":"164","author":"Paul","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.cld.2019.04.011_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.21783","article-title":"Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model","volume":"46","author":"Saab","year":"2007","journal-title":"Hepatology"},{"issue":"26","key":"10.1016\/j.cld.2019.04.011_bib27","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","article-title":"Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis","volume":"30","author":"Zurawska","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cld.2019.04.011_bib28","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","article-title":"Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors","volume":"29","author":"Day","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.cld.2019.04.011_bib29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-015-3382-7","article-title":"Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis","volume":"151","author":"Wong","year":"2015","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:57:00Z","timestamp":1761069420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326119300248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1089326119300248"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2019.04.011","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening and Prophylaxis to Prevent Hepatitis B Reactivation","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2019.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}